Achiko AG Announces Annual Results for the Year Ended 31 December 2021 - Seite 3
The Annual Report is available for download at: https://www.achiko.com/financials/.
The Annual General Meeting of shareholders will take place in July 2022 on a date to be announced in due course
ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.
Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXTM and companion health apps via its digital mobile health technology division, Teman SehatTM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.
Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
Media contacts:
Lesen Sie auch
ACHIKO AG
Investor Relations
E: ir@achiko.com
Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67
Disclaimer
This communication expressly or implicitly contains
certain forward-looking statements concerning Achiko
AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Achiko AG to be materially different
from any future results, performance or achievements expressed or implied by such
forward-looking statements. Achiko AG is providing this
communication as of this date and does not undertake to
update any forward-looking statements contained
herein as a result of new information, future events or
otherwise.